<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="38386">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01765322</url>
  </required_header>
  <id_info>
    <org_study_id>MCHC-2013-01</org_study_id>
    <nct_id>NCT01765322</nct_id>
  </id_info>
  <brief_title>The Effect of Laser-assisted Zona Thinning on the Implantation Rate in the Women of Advanced Age</brief_title>
  <official_title>Center of Assisted Reproductive Technology</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanxi Provincial Maternity and Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanxi Provincial Maternity and Children's Hospital</source>
  <oversight_info>
    <authority>China: State Administration of Traditional Chinese Medicine of the People's Republic of China</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether laser-assisted zona thinning improve the
      implantation rate of the women of advanced age in the first IVF/ICSI cycles
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry procedures：

        1. It's required to sign an informed consent form prior to the recruitment of all
           patients.

        2. Data collection and entry need double check and supervision.

      The outcome measures:

      the implantation rate per embryo transfer miscarriage live birth
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The implantation rate</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>the implantation rate per embryo in first fresh embryos transfer cycles</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The miscarriage</measure>
    <time_frame>24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Female Urogenital Diseases</condition>
  <arm_group>
    <arm_group_label>Assisted hatching group (AH group)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK IVOS Analyzer,Hamilton Thorne Biosciences,USA).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The subjects are going to undergo the same procedure except for the treatment of assisted hatching.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ZILOS-TK IVOS Analyzer</intervention_name>
    <description>The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)</description>
    <arm_group_label>Assisted hatching group (AH group)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 35y ≤age≤46y

          -  Basal FSH value: FSH≤10IU/L

          -  Day-3 embryos transferred in the fresh IVF/ICSI cycles

          -  the number of embryos available to be transferred on Day-3: ≥one embryo

        Exclusion Criteria:

          -  cycles with thawed/warmed embryos biopsied for PGD/PGS.

          -  cycles with oocyte donation transfer.

          -  the maximum number of previous unsuccessful IVF attempts: ≥ 3 cycles(transfer cycles)

          -  any cycles with the risk of OHSS, fluid in the uterine cavity, abnormal endometrium,
             uterine abnormalities,pelvic inflammation, and other acute maternal problems.

          -  One or both spouses have an abnormal karyotype (including polymorphism)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>46 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wenhao Shi, Master</last_name>
    <role>Study Director</role>
    <affiliation>Maternal and Children Health Care Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juanzi Shi, Doctor</last_name>
    <phone>+86-029-87219120</phone>
    <email>shijuanzi123@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maternal and Children Health Care Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shaanxi</state>
        <zip>710003</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenhao Shi, Master</last_name>
      <phone>+86-029-87219120</phone>
      <email>swihao@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 25, 2013</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanxi Provincial Maternity and Children's Hospital</investigator_affiliation>
    <investigator_full_name>Shi Wenhao</investigator_full_name>
    <investigator_title>Assisted Reproductive Technology Center</investigator_title>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urologic Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
